Real-World Incidence and Management of CRS and ICANS in Adults With Newly Diagnosed Philadelphia Chromosome-Positive B-Cell Acute Lymphoblastic Leukemia Treated With Frontline TKI Plus Blinatumomab (SOHO 2026) - Sep 1, 2026 - Abstract #ALL-1307; Location: LEVEL 3, HALL B3; "Twenty-nine patients (97%) received ponatinib, and 1 received asciminib due to cardiac comorbidities...All CRS resolved within 24 hours with supportive care ± corticosteroids; no patients required tocilizumab or treatment discontinuation... Frontline TKI plus blina demonstrated a low incidence of high-grade CRS and ICANS in this real-world cohort. Toxicities were early, brief, and manageable, supporting the feasibility and tolerability of this approach in adults with newly diagnosed PH+ B-ALL. ALL: acute lymphoblastic leukemia; ASTCT: American Society for Transplantation and Cellular Therapy; BCR-ABL: breakpoint cluster region-Abelson 1; CRS: cytokine release syndrome; EHA: European Hematology Association; hyper-CVAD: hyperfractionated cyclophosphamide, vincristine, adriamycin (doxorubicin), dexamethasone; ICANS: immune effector cell-associated neurotoxicity syndrome; mini-CVD: reduced-intensity cyclophosphamide, vincristine, and dexamethasone chemotherapy..."
Clinical • Real-world • Real-world evidence • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • ABL1 • BCR
|
|
Rosa Ancaya MPAS,PA-C; Emma Matzinger; David Swoboda MD; Daniel Kerr MD PhD; Nikesh Shah MD
|